(NASDAQ: KZIA) Kazia Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 37%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41.92%.
Kazia Therapeutics's earnings in 2025 is -$18,446,946.On average, 4 Wall Street analysts forecast KZIA's earnings for 2026 to be -$96,080,708, with the lowest KZIA earnings forecast at -$119,386,920, and the highest KZIA earnings forecast at -$69,898,665. On average, 3 Wall Street analysts forecast KZIA's earnings for 2027 to be -$101,852,340, with the lowest KZIA earnings forecast at -$97,858,131, and the highest KZIA earnings forecast at -$104,847,997.
In 2028, KZIA is forecast to generate -$96,307,046 in earnings, with the lowest earnings forecast at -$92,525,861 and the highest earnings forecast at -$99,136,278.